Gregory Durm (Greg Durm, Greg A Durm)

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 4

Top Topics

Palliative Care

High Throughput

Cross Sectional

Small Cell Lung Cancer

Top Venues

JCO oncology practice

This page only lists publications with an associated author ORCID identifier.

Publications

Maitri Kalra, Elizabeth Henry, Kelly E McCann, Meghan S Karuturi, Jean G Bustamante Alvarez, Amanda Parkes, Robert Wesolowski, Mei Wei, Sarah S Mougalian, Gregory Durm, Angel Qin, Caitlin A Schonewolf, Meghna S Trivedi, Avan J Armaghani, Frederick H Wilson, Wade T Iams, Anita A Turk, Praveen Vikas, Michael Cecchini, Sam Lubner, Priyadarshini Pathak, Kristen Spencer, Vadim S Koshkin, Matthew Kyle Labriola, Catherine Handy Marshall, Kathryn E Beckermann, null null, Marina N Sharifi, Anthony C Bejjani, Varsha Hotchandani, Samir Housri, Nadine Housri
Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. JMIR cancer 8 (2) (2022)
Tareq Salous, Nikhil A Shukla, Sandra K Althouse, Susan M Perkins, Muhammad Furqan, Ticiana Leal, Anne M Traynor, Lawrence E Feldman, Nasser H Hanna, Gregory Durm
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029. Cancer (2022)
Nikhil Shukla, Nasser Hanna, Gregory Durm
Optimal Duration of Maintenance Checkpoint Inhibitor Therapy in Patients With Advanced NSCLC. JCO oncology practice 17 (8) (2021)
Gregory Durm, Salma K Jabbour, Sandra K Althouse, Ziyue Liu, Ahad A Sadiq, Robin T Zon, Shadia I Jalal, Goetz H Kloecker, Michael J Williamson, Karen L Reckamp, Robert M Langdon, Ebenezer A Kio, Ryan D Gentzler, Bamidele A Adesunloye, Wael A Harb, Radhika V Walling, Michael L Titzer, Nasser H Hanna
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Cancer 126 (19) (2020)